Franklin Resources Inc. grew its holdings in shares of Catalent Inc (NYSE:CTLT) by 0.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,407,620 shares of the company’s stock after buying an additional 1,801 shares during the quarter. Franklin Resources Inc. owned 2.34% of Catalent worth $155,217,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Atria Investments LLC boosted its holdings in shares of Catalent by 12.6% in the third quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock valued at $465,000 after purchasing an additional 1,144 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in shares of Catalent by 2.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 51,962 shares of the company’s stock valued at $2,177,000 after purchasing an additional 1,299 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Catalent by 9.7% in the third quarter. State of Alaska Department of Revenue now owns 15,648 shares of the company’s stock valued at $712,000 after purchasing an additional 1,378 shares during the period. United Services Automobile Association boosted its holdings in shares of Catalent by 6.4% in the second quarter. United Services Automobile Association now owns 23,725 shares of the company’s stock valued at $994,000 after purchasing an additional 1,418 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its holdings in shares of Catalent by 1.2% in the third quarter. State Board of Administration of Florida Retirement System now owns 129,724 shares of the company’s stock valued at $5,909,000 after purchasing an additional 1,567 shares during the period. Hedge funds and other institutional investors own 96.77% of the company’s stock.
Shares of CTLT opened at $39.65 on Monday. Catalent Inc has a 12 month low of $34.24 and a 12 month high of $47.87. The company has a quick ratio of 1.61, a current ratio of 2.05 and a debt-to-equity ratio of 1.44. The firm has a market cap of $5.76 billion, a PE ratio of 24.94, a price-to-earnings-growth ratio of 2.48 and a beta of 1.44.
In related news, SVP Lance Miyamoto sold 6,525 shares of the company’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was purchased at an average cost of $43.00 per share, for a total transaction of $430,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 184,335 shares of company stock valued at $8,161,727. Company insiders own 1.40% of the company’s stock.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a report on Monday, October 1st. UBS Group assumed coverage on Catalent in a report on Tuesday, October 9th. They set a “neutral” rating and a $48.00 target price for the company. JPMorgan Chase & Co. upped their target price on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday, August 29th. Royal Bank of Canada set a $45.00 target price on Catalent and gave the stock a “buy” rating in a report on Friday, November 16th. Finally, Robert W. Baird assumed coverage on Catalent in a report on Thursday, November 15th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $48.22.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How Buying a Call Option Works
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.